Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

Celcuity’s stock jumps after Phase 3 trial shows gedatolisib slashes progression risk in breast cancer patients by up to 76%.

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Celcuity shares soar 186% after Phase 3 breast cancer trial shows triple therapy delays disease by over 7 months.

Celcuity Inc. (NASDAQ:CELC) saw its stock soar by more than 100% on Monday following the release of groundbreaking Phase 3 ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

Breast cancer rates among women are on the rise, and doctors are pointing to alcohol as a potential contributing factor.

Prolonged sitting time increases breast cancer risk in obese women, but physical activity may mitigate this association, ...

Cassandra and Katelyn Harding suffered the loss of their mother before both being diagnosed with rare osteosarcoma ...

Bone health management varies across hospitals for older women with early breast cancer who have inconsistent bone density ...

Being one of the most common causes of cancer in women, breast cancer changes a person’s life in many ways. However, this ...